Devastating economical impact

Few comprehensive data exist on the costs associated with sexually transmitted infections. From the information that is available, however, it is clear that the economic burden imposed by these infections is extremely high, and that an increasing proportion of the costs is being borne by public sources of payment. Costs related to STDs will have a devastating impact on Western European countries in the future unless we, the cultural conservatives, manage to seize political and military control and drastically reverse the ongoing cultural suicide of Europe.

HIV/AIDS, 120-300 billion Euro annually (Western Europe)

The direct and indirect costs associated with HIV and AIDS were approximately 120 billion Euro in 2009. HIV and AIDS are much more costly than other STDs, even though there are fewer cases, because of their long-term and devastating consequences.

Large costs related to subsidising the research of treatments HIV/AIDS is not included but might total as much as 100-200 billion Euro annually.

PID, 10-20 billion Euro annually (Western Europe)

On second place comes the cost related to PID, Pelvic inflammatory disease caused by untreated gonorrhea and chlamydia. PID affects millions of women each year in Western Europe and is an infection of one or more pelvic organs, including the uterus, cervix, and fallopian tubes. In 2009, the direct and indirect costs of treatment of PID and PID-related ectopic pregnancy and infertility in women aged 15-44 totaled an estimated 10 billion Euro. This includes direct medical expenses, hospital charges, physician fees, inpatient, care for PID-related ectopic pregnancy and infertility.

Included are indirect costs, which represent the lost productivity of women who are incapacitated by or die prematurely from PID, lost wages, lost value of household management not performed because of illness and indirect costs associated with early deaths related to PID.

Chlamydia, 5-10 billion Euro annually (Western Europe)

Aproximately 8-15 million cases of chlamydia occurs annually in all Western European countries (2009 estimate).

The direct and indirect costs of diagnosing and treating uncomplicated chlamydia and gonorrhea are high and totaled an estimated 5-10 billion Euro in 2009. Included are costs related to direct and indirect costs associated with diagnosis and treatment of pneumonia, conjunctivitis and other problems in infants born with chlamydia transmitted from their mothers during childbirth. Included are also direct and indirect costs of chlamydial infections for both men and women – urethritis and epididymitis.

Gonorrhea and herpes, 2-5 billion Euro annually (Western Europe)

Gonorrhea and herpes also exact a large financial toll, although existing cost data on these diseases are less comprehensive than those on chlamydia. The total cost include the medical care costs of diagnosing and treating uncomplicated gonorrhea, indirect costs, diagnosis and treatment of genital herpes, treatment of neonatal herpes and screening pregnant women for genital herpes.